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We studied 298 patients with severe aplastic anaemia (SAA) allografted in four Latin American countries. The source of cells
was bone marrow (BM) in 94 patients and PBSCs in 204 patients. Engraftment failed in 8.1% of recipients with no difference
between BM and PBSCs (P= 0.08). Incidence of acute GvHD (aGvHD) for BM and PBSCs was 30% vs 32% (P= 0.18), and for grades
III–IV was 2.6% vs 11.6% (P= 0.01). Chronic GvHD (cGvHD) between BM and PBSCs was 37% vs 59% (P= 0.002) and extensive 5% vs
23.6% (P= 0.01). OS was 74% vs 76% for BM vs PBSCs (P= 0.95). Event-free survival was superior in patients conditioned with
anti-thymocyte globulin (ATG)-based regimens compared with other regimens (79% vs 61%, P= 0.001) as excessive secondary graft
failure was seen with other regimens (10% vs 26%, P= 0.005) respectively. In multivariate analysis, aGvHD II–IV (hazard ratio (HR)
2.50, conﬁdence interval (CI) 1.1–5.6, P= 0.02) and aGvHD III–IV (HR 8.3 CI 3.4–20.2, Po0.001) proved to be independent negative
predictors of survival. In conclusion, BM as a source of cells and ATG-based regimens should be standard because of higher GvHD
incidence with PBSCs, although the latter combining with ATG in the conditioning regimen could be an option in selected high-risk
patients.
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INTRODUCTION
Allogeneic haematopoietic stem cell transplantation is considered
the treatment of choice with curative potential for severe
aplastic anaemia (SAA).1 Bone marrow (BM) is regarded as the
best source of stem cells in HLA-matched related and unrelated
transplantation for SAA, as a survival advantage and less
GvHD have been found in large retrospective studies that
compare BM with PBSCs.2,3 In high-income countries, BM is the
main source of stem cells, whereas in countries with limited
resources, where haematology teams face referral of patients in
advanced stages, heavy pretreatment and HLA allo-sensitization
due to multiple transfusions, the use of PBSCs is frequent.4,5
Regarding conditioning regimens, anti-thymocyte globulin
(ATG)-based regimens are the standard of care, but because of
ﬁnancial or bureaucratic constraints in countries with limited
government-supported health-care systems, regimens without
ATG are also frequently used. The objective of this study
was to analyse the long-term results of a large, multicentre
cohort of patients with SAA allografted in four Latin American
countries (LAc), the outcomes with different conditioning
regimens and the source of stem cells. Results are compared
with those of large SAA studies and, as a ﬁnal aim, we provide an
overall perspective of the experience of allografting SAA patients
in our region.
MATERIALS AND METHODS
We included 298 patients with acquired SAA and a ﬁrst transplant
diagnosed between 1990 and 2014 who received an allogeneic
haematopoietic stem cell transplant using BM or PBSC at 19 centres in
four LAc. We analysed the overall survival (OS) of the entire cohort and
then split it into two groups: the ﬁrst included 94 BM-allografted patients
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from Argentinian centres, whereas the second included 204 PBSC-
transplanted patients from Mexico, Peru and Colombia. All cases were
submitted to an institutional review board and transplant committee for
approval; written informed consent was obtained from patients and
donors. The choice of conditioning regimens was made according to each
institution’s guidelines and were grouped into two different categories: (1)
the ATG-based regimens included cyclophosphamide (CY)+ATG (equine or
rabbit-derived), CY+ATG and ﬂudarabine (CY+ATG+FLU) and CY+ATG+TBI;
(2) other regimens that were FLU based included CY+FLU, CY+FLU
+alemtuzumab (CY+FLU+ALEM), CY+FLU+busulfan (CY+FLU+BU) and FLU
+BU; CY-based regimens included CY alone, CY+TBI and BU+CY.
Doses of regimens are speciﬁed in Supplementary Table 1. All regimens
were compared against ATG-based regimens. All donors were full
HLA-identical siblings. PBSCs were collected after donor stimulation with
G-CSF at 10–15 μg/kg. Patients were classiﬁed as multi-transfused if they
had received ⩾ 20 units of packed red cell or platelet concentrates. Post-
transplant (PT) neutrophil and platelet recovery was deﬁned as three
consecutive days with an absolute count ⩾ 500× 109/L and ⩾ 20 × 109/L,
respectively, unsupported by transfusions. Primary outcomes were OS
from transplant until the occurrence of an event (death) and event-free
survival (EFS) from the day of transplant to the occurrence of death or
relapse. Secondary outcomes included incidence of GvHD, primary and
secondary graft failure (GF) and the effect of conditioning regimen on
survival.
Each statistics department of each centre assessed the quality of data
and several authors were involved in internal data audits. Comparisons
of categorical values were carried out using the χ2 test and the
Mann–Whitney test for continuous variables. OS and EFS were calculated
using the Kaplan–Meier method and outcome variables were compared in
subgroups of patients by the log-rank test. Incidence of grade II–IV and
III–IV acute GvHD (aGvHD) and limited or extensive chronic GvHD (cGvHD)
were reported using standardized criteria.6–8 GF, day 100 mortality, GvHD
and relapse were summarized using cumulative incidences with 95%
conﬁdence intervals (CIs) taking into account death as a competing risk
and compared using Gray’s test. Univariate Cox regression analysis was
performed to assess the effect of treatment, source of stem cells and GvHD
as a time-dependent covariate, with two-sided P-values of ⩽ 0.05
considered as statistically signiﬁcant; pertinent variables were used to ﬁt
a multivariate analysis. Data were analysed using SPSS version 22 (SPSS
Inc., Chicago, IL, USA) and cumulative incidence with competing risks and
Gray’s test with R commander software packages 2.2–3 (R Development
Core Team, Vienna, Austria) and EZR by Y Kanda in the Division of
Hematology of Saitama Medical Center.9
RESULTS
Overall, 298 patients received an allogeneic BM (n= 94) or PBSC
(n= 204) transplant. Characteristics of patients and conditioning
regimens used are shown in Table 1. Data on previous treatment
were available for 173 patients; 81 (27%) did not receive any kind
of immunosuppressive therapy; 50 (16.7%) were treated with ATG
+cyclosporine A (CsA) and 42 (14%) with androgens, CsA, steroids
or combinations of these medications. Data for 125 patients (42%)
were not reported.
Of the 219 (73.5%) patients treated with ATG-based regimens,
61 (27.9%) received equine ATG (Atgam, Pﬁzer, New York, NY,
USA) and 158 (72.1%) rabbit-derived ATG (Thymoglobulin, Sanoﬁ,
Gentilly, France). Most patients (61%, n= 183) were treated during
2001–2010, when the use of PBSCs was more frequent in LAc
because of the ease and lower cost of collection. All patients
received GvHD prophylaxis and regimens were heterogeneous:
80% (n= 239) received methotrexate at 10–15 mg/m2 in three to
four doses on days +1, +3, +6 and +11 as well as CsA at 3–5 mg/kg
targeting a serum concentration of 250–350 ng/mL; 9.4% (n= 28)
received CsA 3–5 mg/kg+mycophenolate mofetil 2 g/day from
days 1 to 28; 7.7% (n= 23) received CsA alone at 3–5 mg/kg; and
2.7% (n= 8) received CsA 3–5 mg/kg+methylprednisolone at
0.5–2 mg/kg/day for at least 30 days. All patients received
antibacterial, antifungal and antiviral prophylaxis during the phase
of aplasia and regimens were heterogeneous but mainly
consisted of levoﬂoxacin/ciproﬂoxacin, ﬂuconazole and acyclovir.
Co-trimoxazole was started on day − 6, discontinued 1 day before
stem cell infusion and restarted after neutrophil recovery. The
median dose of CD34+ cells administered was 3.96 × 106 (range
0.40–43.6)/kg of recipient body weight.
Haematopoietic recovery and primary GF
The cumulative rate of engraftment for BM and PBSCs was 88%
and 94% (P= 0.08). G-CSF was not routinely used PT. Median
neutrophil recovery was documented at day 19 (range 9–42) and
11 (range 7–35) (Po0.001) for BM and PBSCs, respectively.
For platelets, median recovery was at day 24 (range 12–104)
and day 12 (range 7–28) (Po0.001) for BM and PBSCs,
respectively. Twenty-one patients died before engraftment, 17
because of infections; in 4 no speciﬁc cause was reported.
Comparing patients conditioned with ATG-based regimens
(74%, n= 219) against those receiving other regimens
(26%, n= 79), more patients failed to engraft with the latter
(6% vs 14%, P= 0.01). We could not obtain the transfusion history
of the BM-allografted group, but 58% of patients in the PBSC
group were considered multi-transfused and no relationship
between receiving multiple transfusions and primary GF was
found (P= 0.78).
Secondary graft failure
In total, 8% of patients (n= 22) lost their grafts, and more patients
who did so received regimens different from ATG-based regimens
(10% vs 26%) (P= 0.005). BM vs PBSC graft loss was 18% vs 13%
(P= 0.75), respectively. Patients in the PBSC group considered
heavily transfused (58%) were at no higher risk of secondary GF
(P= 0.60).
Table 1. Baseline clinical characteristics of patients and conditioning
regimens used
Source Bone marrow
(n= 94)
Peripheral blood
(n= 204)
P-value
Age in years,
median (range)
19 (2–52) 29 (2–65) o0.001
o21 Years, n (%) 58 (61) 64 (31.4) o0.001
Sex male, n (%) 63 (67) 128 (62.7) 0.51
Days from
diagnosis to
transplant,
median (range)a
86.5 (21–4350) 202.5 (21–4436) o0.001
ATG-based
regimens, n (%)
74 (78.7) 145 (71.1) 0.204
Other regimens,
n (%)
20 (21.3) 59 (28.9)
Year of transplant, n (%)
1990–1995 2 (2.1) 3 (1.5)
1996–2000 28 (29.8) 16 (7.8)
2001–2005 17 (18.1) 59 (28.9)
2006–2010 27 (28.7) 80 (39.2)
2011–2015 20 (21.3) 46 (22.5)
Number of patients included by country, n (%)
Mexico 62 (30.4)
Peru 69 (33.8)
Colombia 73 (35.8)
Argentina 94 (100)
Follow-up of
survivors,
median (range)
in days
2454 (202–7645) 2106 (76–8289)
Abbreviation: ATG= anti-thymocyte globulin. aTwo patients received ATG
and androgens with response for more than 10 years and then were
allografted in relapse.
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GvHD
The cumulative incidence of acute GvHD grades II–IV (aGvHD)
and cGvHD for BM and PBSCs was 30% vs 32% (P= 0.189) and
37% vs 59% (P= 0.002), respectively. Regarding aGvHD grades
III–IV, incidence was lower with BM (2.6%) compared with PBSCs
(11.6%) (P= 0.010); the same holds true for extensive cGvHD
with BM (5%) compared with PBSCs (23.6%) (P= 0.005; Table 2).
Taking into consideration conditioning regimens, the incidence
of aGvHD grades II–IV was 30% for ATG-based regimens and
38% for other regimens (P= 0.033). For cGvHD and ATG-based
regimens, incidence was 50% vs 54% for other regimens (P= 0.11)
and no difference in extensive cGvHD between ATG-based
regimens and other regimens (18.6% vs 11.1%, P= 0.80) was
documented.
Age was not associated with the development of GvHD. The
incidence of aGvHD grades II–IV (P= 0.61) and grades III–IV
(P= 0.89) was not statistically different in patients older than 21
years; the same was true for cGvHD (P= 0.39) and extensive
cGvHD (P= 0.49).
Secondary malignancies
Seven patients (2.2%) were diagnosed with secondary
malignancies, after a median of 1099 days PT (30–2780). Four
patients developed AML, one was diagnosed with hairy cell
leukaemia, and two patients developed solid malignancies
(ovarian and tongue cancer).
Causes of mortality
Seventy-nine (26.5%) patients died with a median follow-up of
215 days (4–4423 days). The most common causes of death were
infection in 26 patients (33%), GvHD in 21 (27%), graft failure
o100 days PT in 17 (20%) and 4100 PT in 6 (7%), secondary
neoplasia in 4 (5%), and other causes in 5 patients (6%). Infectious
agents identiﬁed included CMV, Aspergillus, H1N1 and
mucormycosis. Mortality within the ﬁrst 100 days PT for BM and
PBSCS was 6% vs 8% (P= 0.42) and not statistically different
between ATG-based regimens (8%) and all other regimens (15%)
(P= 0.07). Overall risk of death between ATG-based regimens and
all other regimens was statistically signiﬁcant (P= 0.005, hazard
ratio (HR) 1.92, CI 1.2–3.02).
OS and EFS
The median OS of the entire cohort was 76% at 5-year follow-up
and 68% at 10-year PT (Figure 1a). Median follow-up of surviving
patients was 2140 days (range 76–8289). Survival at 5-year PT was
74% vs 76% (P= 0.95) and EFS 70% vs 73% (P= 0.64) for BM and
PBSCS, respectively (Figures 1b and c). Twenty-one patients died 5
years after transplant, mostly because of infections related to
cGvHD and its treatment and also from secondary malignancies.
OS comparison between ATG-based regimens and all other
regimens was 80% vs 65% at 5 years (P= 0.004; Figure 1d).
Regarding EFS at 5 years, ATG-based regimens (79%) were
superior to all other regimens (61%) (P= 0.001). OS of patients
⩾ 21 years old (38%, n= 122) was 76% and analysing those who
received BM or PBSCs was 73% vs 78%, (P= 0.61) at 5-year PT.
Patients ⩾ 21 years old (62%, n= 176) had an OS of 75% at 5 years,
similar to younger patients (P= 0.52); on the other hand, OS for
patients younger or older than 40 years was 80% vs 75% (P= 0.91),
respectively. The median time from diagnosis to transplant was
157 days (range 21–4436). Transplantation beyond this time was
not a predictor of death (P= 0.71; Table 3).
Multivariate analysis
Pertinent variables were included in a multivariate analysis.
Presence of aGvHD II–IV (HR 2.50, CI 1.1–5.6, P= 0.02) and aGvHD
III–IV (HR 8.3, CI 3.4–20.2, Po0.001), proved to be independent
negative predictors of survival (Table 4).
DISCUSSION
We report the results of a large cohort of patients allografted in
four LAc and conﬁrm the positive impact of ATG in the
conditioning regimen as well as the increased risk of GvHD
related to the use of PBSCs. Currently, BM-derived cells and CY in
combination with ATG is the standard of care for SAA in the
setting of transplantation from HLA-identical sibling donors. We
could not detect a signiﬁcant difference in OS between BM and
PBSCs; however, larger and more robust studies have supported
these concepts.2,3,10 Acknowledging the aforementioned studies,
BM as a source of stem cells should be the standard of care, and
PBSC+ATG-based regimens may have a role in selected cases,
such as heavily transfused patients, or in the case of a second
transplant once BM has failed. Recently, a study by Kumar et al.11
described the same phenomena; they found that OS was
higher with BM in high-income countries, whereas in
upper-middle income countries and low-income countries there
was no survival difference between BM and PBSCs, suggesting
that PBSCs may be an alternative to BM in patients living in
countries with limited resources at high risk of graft failure
because of multiple transfusions preceding allografting, among
other reasons.
The cohort of BM allografted patients had a survival of 74%,
lower than that reported by WPSAA-EMBT (84%)2 and CIBMTR
(85%).3 There are several explanations for these differences in
survival; for instance, 20 patients (21%) in this group did not
receive ATG, and 12% suffered primary failure resulting in the
majority of cases in death and had a median of an 8- and 12-day
delay in neutrophil and platelet recovery, respectively, exposing
them to infectious and bleeding complications. Regarding
patients allografted with PBSCs, OS in our study was 76%,
comparable to 68% reported by WPSAA-EBMT.2 In this setting, a
Table 2. Comparison of cumulative incidence of graft failure, day 100 mortality and GvHD according to the source of stem cells
Bone marrow PBSCT P-value
Patient number 94 204
Primary graft failure 13% CI (6.4–19.9) 6% CI (3.3–9.9) 0.08
Day 100 mortality 6.3% CI (1.3–11.2) 7.8% CI (4.0–11.4) 0.95
aGvHD grades II–IV 30% CI (16.8–44.3) 32% CI (20.2–43.7) 0.18
aGvHD grades III–IV 2.6% CI (0.5–8.3) 11.6% CI (7.4–16.7) 0.01
Chronic GvHD 37% CI (20–55) 59% CI (38.3–74.8) 0.002
Extensive cGvHD 5% CI (0.8–15.1) 23.6% CI (10.6–39.4) 0.005
Secondary graft failure 18% CI (5.6–37) 13% CI (6.5–20.7) 0.75
Abbreviations: aGvHD= acute GvHD; CI= conﬁdence interval; cGvHD= chronic GvHD.
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large proportion of PBSC allografted patients (72%) received
ATG during conditioning and, even with an increased
incidence of GvHD, achieved prolonged survival. Our data
indicate no difference in the cumulative rate of engraftment
between BM and PBSCs (87% vs 94%, P= 0.08), although there was
a tendency to have less primary graft failure with PBSCs. These
ﬁgures might be related to the fact that the dose of CD3+
lymphocytes in the PBSC grafts is larger, yielding faster
haematologic recovery; other studies have reported the same
phenomena.2,10
The upper age limit for HLA-matched sibling transplant as ﬁrst-
line therapy for SAA is different in transplant centres around the
world, but it is considered to be 40 years.12,13 In this scenario, 17%
(n= 52) of our patients were 440 years old and 75% survived
beyond 5 years. In some LAc, such as Mexico, allografting is
frequently offered as ﬁrst-line treatment for many patients 440
years old who have an HLA-related donor and who are reasonably
ﬁt when undergoing the procedure.14,15 This selection criterion
may have biased a better result for OS than has been reported for
the general population in this age range and may explain the lack
of difference in OS in this group when compared with younger
patients.
We had incomplete data related to transfusion history in the BM
group, but in the PBSC group, as many as 58% of patients were
considered heavily transfused and most likely HLA allo-sensitized.
This factor, however, was not associated with increments in graft
rejection, relapse or in incidence of GvHD. In patients living in
countries with government-supported health-care systems limited
in ﬁnancial resources, graft rejection is a major concern. A study
from Brazil using BM as the source of stem cells and CY+BU as the
conditioning regimen reported a rejection rate of 43% in heavily
transfused patients;16 in a study from India, 31% of the transplants
performed in SAA patients were ineffective because of graft
rejection.17 In contrast, in a study where 62.3% of patients were
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Figure 1. Outcomes. (a) overall survival of the entire cohort, (b) survival according to the stem cell source, (c) EFS between BM and PBSCs and
(d) survival according to conditioning regimens.
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considered high risk based on, among other factors, multiple
previous transfusions, 90% were transplanted using FLU-based
regimens and PBSCs, achieving successful grafting in 96% and a
5-year OS of 75.5%.18 The observation that high-risk patients may
achieve durable engraftment with PBSCs has also been reported
in a study conducted in the United States, where 26 patients
achieved deﬁnite engraftment with CY and an ATG+FLU
combination but at the cost of a high incidence of aGvHD
and cGvHD.
Exploring secondary GF with PBSCs and BM, large studies have
reported an incidence of 1.4–6% and 1.3–12%, respectively.2,3 In
our study, secondary graft rejection was 18% vs 13% (P= 0.75)
with BM and PBSCs, respectively, and this was considered to be
related to the conditioning regimen, not to the source of stem
cells, as signiﬁcantly more patients who lost their grafts did not
receive ATG as part of their conditioning regimen.
Considering patients who developed AML or a myelodysplastic
syndrome, it is important to underscore that they could have been
misdiagnosed as having SAA or may have developed clonal
evolution related to exposure to alkylating agents; it has also been
reported that patients with Fanconi anaemia may present with a
constellation of malignancies such as the patient who developed
tongue cancer.
Our study has several limitations, including its retrospective
design, the relatively small number of patients in the BM group
and the lack of complete blood transfusion history in the BM
patients; nonetheless, it provides the ﬁrst general perspective of
the treatment of SAA in Latin America.
In conclusion, our experience with BM and PBSCs as sources of
stem cells has shown that successful engraftment is possible for
patients in countries with limited resources. The use of CY and ATG
or the ATG+FLU combination was a predictor of deﬁnite
engraftment as an excessive secondary GF was seen with other
conditioning regimens. Ideally, the use of BM as the source of stem
cells should be the standard of care; however, PBSCs in this
real-world scenario might be an option in selected cases such as
Table 3. Univariate analysis of factors inﬂuencing OS in the study population
5-Year OS, n (%) (95% CI) P-value HR (95% CI) P-value
Age at allo-HSCT
o21 Years (n= 122) 93 (76%) (67–83) 0.523 1
421 Years (n= 176) 132 (75%) (68–81) 1.15 0.37–1.8 0.524
Time from diagnosis to allo-HSCT
o157 Days (n= 149) 76 (76%) (68–82) 0.715 1
4157 Days (n= 149) 84 (75%) 1.09 0.69–1.68 0.71
Conditioning regimen
ATG-based regimen (n= 219) 175 (80%) (73–84) 0.003 1
Other regimen (n= 79) 51 (65%) (53–74) 1.92 1.2–3.02 0.005
Class of ATG
Horse ATG (n= 61) 44 (72%) (60–81) 0.237 1
Rabbit ATG (n= 158) 133 (84%) (76–88) 0.69 0.3–1.2 0.23
Multi-transfused (PBSC)
No (n= 86) 68 (79%) (68–86) 1
Yes (n= 118) 91 (77%) (68–83) 0.278 1.36 0.77–2.3 0.28
Source of HSC
Bone marrow (n= 94) 69 (74%) (63–82) 0.954 1
PBSC (n= 204) 157 (76%) (70–82) 1.014 0.63–1.62 0.95
GvHD prophylaxis
CsA+MTX (n= 239) 184 (77%) (70–81) 0.28 1
Other (n= 59) 42 (72%) (59–82) 1.020 0.84–1.23 0.84
Year of transplant
⩽ 2005 (n= 125) 86 (69%) (60–76) 0.04 1
After 2006 (n= 173) 140 (81%) (74–86) 0.62 0.39–0.99 0.46
aGvHD II–IV
No (n= 205) 186 (91%) (86–94) 1
Yes (n= 93) 40 (43%) (29–56) o0.0001 6.9 (4.1–11.6) o0.0001
aGvHD III–IV
No (n= 272) 242 (89%) (84–92) 1
Yes (n= 26) 1 (5.3%) (0.5–22) 40.0001 14 6.9–28.1 o0.0001
cGvHD
No (n= 143) 120 (84%) (78–88) 1
Yes (n= 155) 102 (66%) (53–76) o00001 2.40 1.4–3.9 0.001
cGvHD extensive
No (n= 245) 206 (84%) (78–88) 1
Yes (n= 53) 23 (43%) (23–62) o0.0001 4.3 2.4–7.7 o0.0001
Abbreviations: aGvHD= acute GvHD; allo-HSCT= allogeneic haematopoietic stem cell transplant; ATG= anti-thymocyte globulin, CI= conﬁdence interval;
cGvHD= chronic GvHD; CsA= cyclosporine; HR= hazard ratio; MTX=methotrexate; OS=overall survival.
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failure of a BM transplant or in heavily transfused patients as the
increased risk of GvHD with PBSCs seems to outweigh the
complications related to the prolonged aplastic phase or primary
graft failure seen in BM transplants in high-risk patients living in
countries with limited government-supported health-care systems.
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Table 4. Multivariate analysis of covariates inﬂuencing survival
Covariate HR (95% CI) P-value
Multivariate analysis
ATG in conditioning
ATG-based regimen (n= 219) 1
Other regimen (n= 79) 1.13 0.65–1.98 0.65
aGvHD II–IV
No 1
Yes 2.50 1.1–5.6 0.028
aGvHD III–IV
No 1
Yes 8.3 3.4–20.2 o0.001
cGvHD
No 1
Yes 1.15 0.53–2.5 0.71
cGvHD extensive
No 1
Yes 1.09 0.45–2.6 0.83
Year of transplant
⩽ 2005 (n= 125) 1
After 2006 (n= 173) 0.54 0.3–0.98 0.04
Abbreviations: aGvHD= acute GvHD; ATG= anti-thymocyte globulin,
CI= conﬁdence interval; cGvHD= chronic GvHD; HR=hazard ratio.
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